

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Any Adverse Events	77	22	(35.5%)	65	21	(32.3%)	21	11	(37.9%)	163	54	(34.6%)
Eye disorders	29	14	(22.6%)	26	13	(20.0%)	12	8	(27.6%)	67	35	(22.4%)
Corneal epithelium defect	0	0		6	6	(9.2%)	0	0		6	6	(3.8%)
Blepharitis	1	1	(1.6%)	2	2	(3.1%)	2	2	(6.9%)	5	5	(3.2%)
Corneal erosion	5	2	(3.2%)	2	2	(3.1%)	0	0		7	4	(2.6%)
Cataract	3	3	(4.8%)	0	0		0	0		3	3	(1.9%)
Corneal neovascularisation	2	2	(3.2%)	3	1	(1.5%)	0	0		5	3	(1.9%)
Dry eye	1	1	(1.6%)	1	1	(1.5%)	1	1	(3.4%)	3	3	(1.9%)
Keratitis	0	0		5	3	(4.6%)	0	0		5	3	(1.9%)
Neurotrophic keratopathy	3	2	(3.2%)	1	1	(1.5%)	0	0		4	3	(1.9%)
Ulcerative keratitis	3	3	(4.8%)	0	0		0	0		3	3	(1.9%)
Conjunctival haemorrhage	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)
Conjunctivitis	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Corneal opacity	1	1	(1.6%)	0	0		1	1	(3.4%)	2	2	(1.3%)
Eye pain	0	0		1	1	(1.5%)	1	1	(3.4%)	2	2	(1.3%)
Lacrimation decreased	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Ocular hyperaemia	0	0		0	0		2	2	(6.9%)	2	2	(1.3%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Eye disorders												
Eyelid pain	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Eyelid ptosis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Foreign body sensation in eyes	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Lacrimation increased	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Lenticular opacities	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Meibomianitis	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Ocular discomfort	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Ocular vascular disorder	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Pseudopterygium	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Retinal cyst	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Uveitis	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Visual acuity reduced	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Vitreous haemorrhage	2	1	(1.6%)	0	0		0	0		2	1	(0.6%)
Infections and infestations	12	8	(12.9%)	11	6	(9.2%)	3	3	(10.3%)	26	17	(10.9%)
Nasopharyngitis	3	3	(4.8%)	1	1	(1.5%)	2	2	(6.9%)	6	6	(3.8%)
Helicobacter gastritis	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Infections and infestations												
Herpes ophthalmic	2	2	(3.2%)	0	0		0	0		2	2	(1.3%)
Keratitis herpetic	0	0		3	2	(3.1%)	0	0		3	2	(1.3%)
Bacterial infection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Blister infected	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Catheter site infection	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Corneal abscess	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Corneal infection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Cystitis	0	0		2	1	(1.5%)	0	0		2	1	(0.6%)
Herpes simplex ophthalmic	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Herpes zoster ophthalmic	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Onychomycosis	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Sinusitis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Tonsillitis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Urinary tract infection	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
General disorders and administration site conditions	4	3	(4.8%)	5	3	(4.6%)	0	0		9	6	(3.8%)
Disease progression	2	2	(3.2%)	3	1	(1.5%)	0	0		5	3	(1.9%)
Inflammation	1	1	(1.6%)	1	1	(1.5%)	0	0		2	2	(1.3%)
Impaired healing	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Instillation site pain	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Injury, poisoning and procedural complications	3	3	(4.8%)	2	1	(1.5%)	3	2	(6.9%)	8	6	(3.8%)
Clavicle fracture	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Facial bones fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Fall	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Femur fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Pelvic fracture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Tibia fracture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Transplant failure	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Upper limb fracture	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Investigations	2	2	(3.2%)	3	3	(4.6%)	1	1	(3.4%)	6	6	(3.8%)
Intraocular pressure increased	1	1	(1.6%)	2	2	(3.1%)	1	1	(3.4%)	4	4	(2.6%)
Blood pressure increased	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Investigations												
Heart rate increased	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Gastrointestinal disorders	3	3	(4.8%)	2	2	(3.1%)	0	0		5	5	(3.2%)
Abdominal pain upper	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Dental discomfort	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Diverticular perforation	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Gastric polyps	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Nausea	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Metabolism and nutrition disorders	3	2	(3.2%)	4	3	(4.6%)	0	0		7	5	(3.2%)
Decreased appetite	2	1	(1.6%)	0	0		0	0		2	1	(0.6%)
Gout	0	0		2	1	(1.5%)	0	0		2	1	(0.6%)
Hyperuricaemia	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Hypokalaemia	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Vitamin D deficiency	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Nervous system disorders	1	1	(1.6%)	4	4	(6.2%)	0	0		5	5	(3.2%)
Brain oedema	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Burning sensation	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Headache	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Syncope	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Visual field defect	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Vascular disorders	7	5	(8.1%)	0	0		0	0		7	5	(3.2%)
Aortic dissection	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Aortic rupture	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Deep vein thrombosis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diabetic vascular disorder	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diastolic hypotension	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Hypertension	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Shock haemorrhagic	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Cardiac disorders	4	4	(6.5%)	0	0		0	0		4	4	(2.6%)
Arrhythmia	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Cardiac failure	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Cardiac disorders												
Coronary artery stenosis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Myocardial infarction	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Respiratory, thoracic and mediastinal disorders												
Respiratory failure	2	2	(3.2%)	1	1	(1.5%)	1	1	(3.4%)	4	4	(2.6%)
Dyspnoea	0	0		1	1	(1.5%)	1	1	(3.4%)	2	2	(1.3%)
Epistaxis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Epistaxis	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Renal and urinary disorders												
Renal colic	1	1	(1.6%)	2	2	(3.1%)	0	0		3	3	(1.9%)
Bladder prolapse	0	0		2	2	(3.1%)	0	0		2	2	(1.3%)
Bladder prolapse	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Immune system disorders												
Corneal graft rejection	0	0		3	2	(3.1%)	0	0		3	2	(1.3%)
Immunodeficiency	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Immunodeficiency	0	0		2	1	(1.5%)	0	0		2	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c

Table 14.3.1.2c Summary of Adverse Events by System Organ Class, Preferred Term, Treatment and Overall
(Safety Population)

Study Period: Follow-Up Period

Body System MedDRA Preferred Term	rhNGF 10 µg/ml (N=62)			rhNGF 20 µg/ml (N=65)			Vehicle Control (N=29)			Total (N=156)		
	N*	n	%	N*	n	%	N*	n	%	N*	n	%
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	0	0		1	1	(1.5%)	1	1	(3.4%)	2	2	(1.3%)
Neoplasm recurrence	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Neurofibroma	0	0		0	0		1	1	(3.4%)	1	1	(0.6%)
Blood and lymphatic system disorders	3	1	(1.6%)	0	0		0	0		3	1	(0.6%)
Anaemia	3	1	(1.6%)	0	0		0	0		3	1	(0.6%)
Hepatobiliary disorders	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Cholelithiasis	0	0		1	1	(1.5%)	0	0		1	1	(0.6%)
Musculoskeletal and connective tissue disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Intervertebral disc protrusion	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Reproductive system and breast disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Uterine prolapse	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Skin and subcutaneous tissue disorders	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)
Diabetic foot	1	1	(1.6%)	0	0		0	0		1	1	(0.6%)

N* = Number of Events Reported, n = Number of Patients, % = Percentage of Patients.

Patients allocated to Vehicle Control who are not completely healed at Week 8 are counted in their Uncontrolled Treatment group in the Follow-Up Period. All other patients are counted in their Controlled Treatment group.

Percentages are calculated using the population number in each treatment group (N) as the denominator.

Body system and preferred terms are sorted by descending frequency of patient count in the Total column.

Events are categorised according to the last treatment received from the controlled or uncontrolled treatment periods.

The data presented in this Table are contained in Listing 16.2.7.1c